Indeed, we found that ADORA2A knockdown led to a marked reduction in VEGF-induced HRMEC sprouting and tube formation, suggesting a facilitating role of ADORA2A in the VEGF pathway, the molecular target of current treatments for diabetic eye diseases. Here, VEGFA is linked to diabetic eye disease.